Management and treatment

Management and treatment

While TFOS DEWS II Diagnostic Guidelines provides a stepwise algorithm, real-world clinical practice demands individualized treatment escalation or combination therapy, depending on disease severity, etiology (evaporative vs. aqueous-deficient, with Meibomian Gland Dysfunction (MGD), inflammatory burden, comorbidities, and patient tolerance.[1]

Step 1 — Foundational step

1.Patient education & environmental modification: [34, 45]

  • Reduce triggers (airflow, low humidity, prolonged screen use); improve adherence and expectations.
  • Follow the 20-20-20 rule, a simple and effective way to reduce digital eyestrain caused by too much screen time. By taking a 20-second break every 20 minutes to look at something 20 feet away, you can give your eyes a much-needed rest. [46]
  • It is used as a universal first line for all patients, especially mild intermittent symptoms, and digital workers.

2.Review/modify offending systemic & topical medications: [47]

  • Identify and stop/reduce medications that reduce tear production or damage the ocular surface (e.g., topical preservatives, anticholinergics).
  • It is for suspected iatrogenic DED (e.g., patients on antidepressants, isotretinoin, chronic glaucoma meds).

3.Lid hygiene & warm compresses (manual or heated masks): [47, 48]

  • The heat from the warm compress helps to open the meibomian glands to improve oil gland function, increase oil flow into the eyes, stabilize the tear film, and slow down tear evaporation. [49]
  • Used for posterior blepharitis / MGD-predominant evaporative dry eye; first-line for lid disease.

4.Artificial tears-preservative-free; lipid-containing if MGD present: [47, 50]

  • Replace/augment tear film; choose viscosity and lipid content to match needs; avoid preservatives if frequent use.
  • It is used for mild–to–moderate DED in frequent symptomatic patients.
  • For mild or transient DED, options such as sodium hyaluronate, hydroxypropyl methylcellulose (HPMC), carboxymethylcellulose (CMC), and polyethylene glycol (PEG) are recommended.
  • Severe cases may benefit from a combination of agents, such as sodium hyaluronate with CMC. Trehalose, betaine, glycine, allantoin, ectoine, phospholipids, and artificial tears are also beneficial to the ocular surface.

5.Omega-3 dietary advice/supplementation: [47, 51, 52]

  • Adjunct to improve meibum composition; counsel on variability of evidence.
  • It is used for MGD patients or those seeking adjunctive therapy.
  • Foods rich in omega-3s include fatty fish, like salmon, sardines, mackerel, flaxseeds, chia seeds, and walnuts.
  • Leafy Greens: Spinach, kale, and other leafy greens are rich in lutein and zeaxanthin, antioxidants that protect the eyes from damage and improve overall eye health.
  • Vitamin A is essential for maintaining a healthy tear film. Foods rich in vitamin A include carrots, sweet potatoes, and bell peppers.
  • Citrus Fruits: Vitamin C, included in oranges, grapefruits, and other citrus fruits, is another powerful antioxidant that helps reduce inflammation in the eyes and support healthy tear production.
  • Nuts and Seeds:Almonds, walnuts, and flaxseeds are rich in vitamin E and omega-3 fatty acids. These nutrients work together to protect the eyes from oxidative stress and support tear production.
  • Avoid processed foods since they often contain high levels of unhealthy fats, sugar, and salt, which can contribute to inflammation and exacerbate dry eye symptoms. [53]

Step 2 — Targeted & Pharmacological Treatment

1.Preservative-free optimized artificial tears (adjusted viscosity/lipid): [47]

  • This aims to tailor lubrication to symptoms; reduce toxic preservatives.
  • Used for Patients needing frequent instillation or with preservative sensitivity.

2.Treat Demodex / anterior blepharitis (tea tree oil formulations, in-clinic debridement) [47]

  • Reduce Demodex-associated inflammatory load, mechanical cleaning.
  • Used for patients with collarettes, lash debris, or recalcitrant anterior blepharitis.

3.Tear conservation — punctal occlusion (temporary/silicone plugs) [47, 54]

  • Reduce tear drainage to increase ocular surface residence time of tears/therapeutics.
  • Used for aqueous-deficient patients after inflammation is controlled; consider temporary plugs first.

4.Moisture chamber devices/goggles; overnight ointment [47]

  • Maintain periocular humidity and prolong tear retention during sleep.
  • Nocturnal exposure, severe evaporative cases, and Continuous positive airway pressure (CPAP) users.

5.In-office thermal pulsation & meibomian gland expression (LipiFlow, or manual) [55]

  • Relieve meibomian gland obstruction and restore lipid secretion.
  • Used for moderate-to-severe MGD refractory to warm compresses; often repeated every 6–12 months.

6.Intense Pulsed Light (IPL) ± MG expression [56]

  • It reduces periocular telangiectasia, improves gland function (mechanism partially via vascular/photo-thermal effects).
  • Used for refractory MGD with eyelid telangiectasia or rosacea; consider skin type and contraindications.

7.Topical Corticosteroids (short-term use) [47, 57]

  • They rapidly reduce ocular surface inflammation; use a short course to bridge while immunomodulators take effect; monitor intraocular pressure (IOP) and cataract risk.
  • Used in case of flare-ups, moderate-to-severe inflammation needing quick control before longer-term agents.

8.Topical immunomodulators (cyclosporine A 0.05–0.1%, tacrolimus) [58]

  • They reduce T-cell mediated inflammation; improve tear production and goblet cell density over weeks to months.
  • Used for chronic inflammatory DED that is not controlled with lubricants; aqueous-deficient with inflammatory features.

9.Lifitegrast 5% (LFA-1 antagonist) [59]

  • It blocks lymphocyte adhesion and reduces ocular surface inflammation, resulting in symptomatic improvement in trials within weeks.
  • Used for patients with moderate DED with persistent discomfort despite lubricants, as an alternative or adjunct to cyclosporine.

10.Oral tetracyclines/macrolides (doxycycline, azithromycin) [60, 61]

  • Anti-inflammatory effects, improve meibum composition, and lid margin bacterial profile.
  • Used for refractory MGD with posterior blepharitis, rosacea-associated MGD.

Step 3 — Regenerative/protective

1.Autologous/allogeneic serum eye drops; platelet-rich plasma (PRP) [62]

  • Provide growth factors & tear components that promote epithelial healing and reduce inflammation.
  • Severe epithelial defects (persistent punctate epitheliopathy), neurotrophic keratitis, and refractory severe DED.

2.Oral secretagogues (pilocarpine, cevimeline) [47]

  • Stimulate the residual lacrimal gland secretion systemically.
  • Used for selected severe aqueous-deficient patients (e.g., Sjögren’s) without contraindications.

3.Therapeutic contact lenses such as scleral lenses, bandage soft lenses [47]

  • They create a fluid reservoir over the cornea to protect and hydrate the ocular surface, and improve vision in irregular corneas.
  • Used for severe ocular surface disease, persistent epithelial defects, and symptomatic patients who are refractory to prior measures.

Step 4 — Surgical/advanced

1.Extended topical corticosteroids (specialist supervised) [47]

  • Control severe chronic inflammation when shorter courses fail; close monitoring for IOP/cataract.
  • Used for refractory inflammatory DED with a threat to corneal integrity under specialist care.

2.Amniotic membrane grafting/transplantation [47]

  • Promote epithelial healing, provide an anti-inflammatory substrate for severe ocular surface disease.
  • Persistent epithelial defects, severe keratopathy, ocular surface failure.

3.Permanent punctal occlusion / surgical occlusion [47, 54]

  • Long-term tear conservation in severe aqueous deficiency.
  • Patients benefiting from temporary plugs require long-term retention and have a low inflammatory burden.

4.Other surgical approaches, such as tarsorrhaphy, salivary gland transplantation, and conjunctival procedures [47]

  • They provide mechanical protection or alternative lubrication for end-stage ocular surface disease.
  • Used for end-stage ocular surface failure, severe keratinization, or failed conservative measures, usually with a corneal specialist referral.
Dry eye syndrome is often a progressive condition, and early diagnosis and treatment are crucial to preventing more serious complications. Without proper management, dry eye can worsen over time and lead to a variety of problems that can significantly impact your overall eye health and quality of life. [63]